NASH (non-alcoholic steatohepatitis)
TIGER
Medical Product Study
Recruitment expected Fall 2026
A Randomized, Controlled Study of Oviva Direct to Improve Glycemic Control in Patients With Type 2 Diabetes Mellitus (T2DM)
Objective
Improved glycemic control
We are looking for patients with:
- Type 2 Diabetes
- Ability to use Oviva app on own smart device
If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.
Zenith 1 + 2
EU CT Nummer: 2025-523675-39
EU CT Nummer: 2025-523674-16
Recruitment expected August 2026
Zenith 1: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Zenith 2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Objective
Decrease in fibrosis
We are looking for patients with:
- Metabolic Syndrome (Diabetis type 2, hypertension, hypercholesterolemia)
- liver steatosis (Fibroscan >8kPa <20kPa, MRI-PDFF >8% )
- no liver disease (e.a. Hep B /C)
- no liver cirrhosis
If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.
NaTiV-3
EU CT Number: 2020-004986-38
Recruitment closed
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Objective
Histological decrease in fibrosis (NAS score -2 points) / healing of inflammation
We are looking for patients with:
- Metabolic Syndrome (Diabetis type 2, hypertension, hypercholesterolemia)
- liver steatosis (Fibroscan >6kPa)
- no liver disease (e.a. Hep B /C)
- no liver cirrhosis
If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.
Akero
EU CT Number: 2023-505141-48-00
Recruitment is open
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-3-Studie zur Bewertung der Sicherheit und Wirksamkeit von Efruxifermin bei Patienten mit nicht-zirrhotischer nicht-alkoholischer Steatohepatitis (NASH)/metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH) und Fibrose.
Objective
Histological decrease in fibrosis (NAS score -2 points) / healing of inflammation
We are looking for patients with:
- Metabolic Syndrome (Diabetis type 2, hypertension, hypercholesterolemia)
- liver steatosis (Fibroscan >6kPa)
- no liver disease (e.a. Hep B /C)
- no liver cirrhosis
If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.